[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546278":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":23,"locations":28,"responsibleParty":51,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":23,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":23,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":23,"overallStatus":31,"whyStopped":23,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"obesity status","obesity",[12],"Drug: Insulin",{"label":14,"type":6,"description":15,"interventionNames":16},"lean","non-obese",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Insulin","2 dose insulin infusion 4 hours",[14,9],null,[25],{"name":26,"affiliation":5,"role":27},"Michael Jensen, MD","PRINCIPAL_INVESTIGATOR",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-92.4699,44.02163,{"lat":41,"lon":40},[44,49],{"name":45,"role":46,"phone":47,"phoneExt":23,"email":48},"Madeline S Reid","CONTACT","507-255-0007","reid.madeline@mayo.edu",{"name":50,"role":27,"phone":23,"phoneExt":23,"email":23},"Michael D Jensen, MD",{"type":27,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Michael D. Jensen","Principal Investigator",[55],{"name":56,"class":57},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100546278","early-phase-1-regional-lipolysis-insulin-regulation-100546278",false,"NCT06392854","Regional Lipolysis Insulin Regulation","Insulin Regulation of Regional Lipolysis","Inclusion Criteria:\n\n* Males and females 18-65years who are able to comprehend instructions, follow study procedures and who willing to provide written, informed consent will be included. The volunteers will consume an isoenergetic diet eating all meals from Mayo Clinical Research Trials Unit (CRTU) for 3 days prior to study.\n* Overweight\u002FObese volunteers will have a BMI 29.0 - 37.0 kg\u002Fm2\n\n  * Upper body\u002Fvisceral obesity (UBO) in women will be defined as those with a waist-hip ratio (WHR) \\> 0.85 and\u002For increased visceral fat by single slice CT scan, usually with \\> 120 cm2 of visceral fat by CT scanning or a visceral fat\u002Ftotal fat ratio of \\> 0.30, and\u002For biochemical evidence of metabolic syndrome as defined by ATP III criteria (fasting plasma triglycerides ≥ 150 mg\u002FdL, HDL-cholesterol \\< 50 mg\u002FdL for women and \\< 40 mg\u002FdL for men, fasting plasma glucose ≥ 100 mg\u002FdL). Upper body obesity in men will be defined as a waist-hip ratio of \\>0.95 and\u002For increased visceral fat (visceral fat area \\> 180 cm2 or a visceral\u002Ftotal fat abdominal ratio by CT of \\> 0.40) by single slice CT scan and\u002For biochemical evidence of metabolic syndrome as defined by adenosine triphosphate (ATP) III criteria. These visceral fat values are based upon the data collected at Mayo Clinic using our methods, and are correlated with dyslipidemia and hyperinsulinemia.\n  * Lower body obesity (LBO) in women will be defined as a waist-hip ratio of \\<0.75 and\u002For a lower visceral fat by single slice CT scan, usually \\< 120 cm2 or a visceral fat\u002Ftotal fat ratio of ≤ 0.30 and fasting plasma triglycerides within the normal range. The term \"lower body men\" is used to describe a male phenotype that is characteristic of adipose insulin sensitivity even with excess body fat. A waist to hip ratio isn't suitable for this description as it is for women. LBO men will be defined as obese men with normal fasting plasma triglycerides, normal fasting plasma glucose and greater proportional leg fat via dual-energy x-ray absorptiometry (DEXA).\n* Female subjects are eligible if they meet the following criteria:\n\n  * Are not pregnant or nursing.\n  * All women of childbearing potential will have a negative urine pregnancy test at screening and a negative urine pregnancy test day of admission for inpatient study visit.\n\nExclusion Criteria:\n\n* Individuals with a history of a disease process such as:\n\n  * Ischemic heart disease\n  * Atherosclerotic valvular disease\n  * Persistent blood pressure greater than 160\u002F95 despite antihypertensive medication\n* Smokers\n* Diagnosis Diabetes Mellitus\n* Concomitant use of medications that can alter free fatty acid metabolism, including, but not limited to niacin, thiazolidinediones, beta-blockers, oral or injected corticosteroids or anabolic steroids.\n* Allergy to lidocaine\n* Allergy to indocyanine green.",true,"ALL","18 Years","65 Years",{"count":70,"type":71},48,"ESTIMATED","INTERVENTIONAL",[74],"EARLY_PHASE1","Adults who gain most of their excess weight in the abdominal area typically do not respond to insulin in the same way as lean adults. Researchers are trying to understand why fat tissue responds differently in people with different body types.",[77],"Obesity","2026-04-07",{"date":80,"type":81},"2026-04-13","ACTUAL",{"date":83,"type":81},"2024-05-01",{"date":85,"type":71},"2028-06",{"name":5,"class":6},1]